Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PRE
stocks logo

PRE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
38.30M
+264.76%
0.040
-103.1%
45.90M
+165.13%
0.240
-130%
51.20M
+189.59%
0.360
-138.3%
Estimates Revision
The market is revising Upward the revenue expectations for Prenetics Global Limited (PRE) for FY2025, with the revenue forecasts being adjusted by 5.56% over the past three months. During the same period, the stock price has changed by 72.19%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.56%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-13.28%
In Past 3 Month
Stock Price
Go Up
up Image
+72.19%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Prenetics Global Ltd (PRE.O) is 12.90, compared to its 5-year average forward P/E of -3.22. For a more detailed relative valuation and DCF analysis to assess Prenetics Global Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.22
Current PE
12.90
Overvalued PE
1.85
Undervalued PE
-8.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
5.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
53.82
Undervalued EV/EBITDA
-42.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.30
Current PS
0.00
Overvalued PS
2.23
Undervalued PS
0.36
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PRE News & Events

Events Timeline

(ET)
2025-11-10
07:27:14
Prenetics Announces Q3 Continuing Operations EPS of 41c Compared to 78c Last Year
select
2025-11-04 (ET)
2025-11-04
08:26:01
Prenetics IM8 Reports $9 Million in Revenue for October
select
2025-10-31 (ET)
2025-10-31
08:36:42
Prenetics reveals purchase of 100 Bitcoin
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-25Newsfilter
Prenetics (NASDAQ:PRE) to Participate in Two Investor Conferences with CEO Presentation
  • Investor Conference Schedule: Prenetics will participate in The Benchmark Company's 14th Annual Discovery One-on-One Conference on December 4, 2025, at the New York Athletic Club, where CEO Danny Yeung will engage in one-on-one meetings with investors to enhance interaction and trust.
  • Virtual Conference Participation: The company will also attend Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, with Danny Yeung delivering a formal presentation at 10:00 AM ET on December 10, showcasing the company's innovations and growth potential in health sciences.
  • Rapid Brand Growth: The IM8 brand achieved $108 million in ARR within 12 months of launch, making it the fastest-growing brand in supplement industry history, demonstrating Prenetics' strong competitive position and market appeal.
  • Bitcoin Strategy: As the first consumer health company to establish a Bitcoin Treasury, Prenetics purchases 1 Bitcoin daily, totaling 501 BTC, indicating the company's forward-looking strategy at the intersection of health innovation and digital assets.
[object Object]
Preview
5.0
11-24Newsfilter
Prenetics Executives Purchase 111,911 Shares for $1.45 Million
  • Executive Purchases: Prenetics' executive team acquired a total of 111,911 shares of common stock for approximately $1.45 million during the designated trading window. This move reflects their confidence in the company's long-term vision, potentially boosting investor trust.
  • CEO's Transactions: CEO Danny Yeung purchased 40,118 shares on November 18 and 19 for about $502,000, averaging $12.51 per share. This indicates strong confidence in the company's future, which may positively influence the stock price.
  • Market Impact: The news of executive purchases could heighten market interest in Prenetics, especially given the rapid growth of its IM8 brand. IM8 achieved $100 million in annual recurring revenue within just 11 months of launch, showcasing strong performance in the health tech sector.
  • Bitcoin Strategy: Prenetics continues to advance its Bitcoin strategy, purchasing one Bitcoin daily, totaling 501 BTC. This strategy not only enhances the company's financial resilience but may also attract investors interested in digital assets.
[object Object]
Preview
4.5
11-16WSJ
New Rare-Earths Facility in Europe Highlights Challenges in Reducing Dependence on China

  • Europe's Rare-Earths Initiative: Europe is establishing a significant presence in the global rare-earths market with a new production facility in Narva, Estonia, aimed at reducing reliance on China.

  • Facility Details: The plant, built by Neo Performance Materials and partially funded by the EU, will produce rare-earth magnets essential for electric vehicles and wind turbines, with commercial deliveries expected to start next year.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Prenetics Global Ltd (PRE) stock price today?

The current price of PRE is 13.93 USD — it has decreased -3.2 % in the last trading day.

arrow icon

What is Prenetics Global Ltd (PRE)'s business?

Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.

arrow icon

What is the price predicton of PRE Stock?

Wall Street analysts forecast PRE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRE is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Prenetics Global Ltd (PRE)'s revenue for the last quarter?

Prenetics Global Ltd revenue for the last quarter amounts to 23.56M USD, increased 567.66 % YoY.

arrow icon

What is Prenetics Global Ltd (PRE)'s earnings per share (EPS) for the last quarter?

Prenetics Global Ltd. EPS for the last quarter amounts to -0.53 USD, decreased -36.90 % YoY.

arrow icon

What changes have occurred in the market's expectations for Prenetics Global Ltd (PRE)'s fundamentals?

The market is revising Upward the revenue expectations for Prenetics Global Limited (PRE) for FY2025, with the revenue forecasts being adjusted by 5.56% over the past three months. During the same period, the stock price has changed by 72.19%.
arrow icon

How many employees does Prenetics Global Ltd (PRE). have?

Prenetics Global Ltd (PRE) has 285 emplpoyees as of December 05 2025.

arrow icon

What is Prenetics Global Ltd (PRE) market cap?

Today PRE has the market capitalization of 234.42M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free